FDA reform needs to be underpinned by strategy, not ‘indiscriminate’ cuts The Trump administration could save the lives of ...

The Trump administration has canceled an upcoming meeting of the Food and Drug Administration’s vaccine advisory committee, a ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Q4 2024 Earnings Call Transcript February 27, 2025 Cardiff Oncology, Inc. beats earnings expectations. Reported EPS is $-0.22 ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, addresses how tariffs will affect pharmaceutical costs and which drug categories will be most affected.

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisors IRDr.